JACC. Clinical electrophysiology · 2026
Ventricular Arrhythmias After Self-Expanding Transcatheter Pulmonary Valve Replacement: A Report From the SERVE Registry.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Armstrong Aimee K, Goldstein Bryan H, Aboulhosn Jamil, Balzer David, Barry Oliver M, Berman Darren P, Boe Brian A, Bocks Martin L, Cabalka Allison K, Fraint Hannah, Kanter Joshua, Keeshan Britton, Lamers Luke, Ligon R Allen, Maschietto Nicola, McMahon William S, Qureshi Athar M, Shahanavaz Shabana, Stefanescu Schmidt Ada C, Suntharos Patcharapong, Whiteside Wendy, Zablah Jenny E, Zahn Evan, Zampi Jeffrey D, Zellers Thomas, Eazer Julia, Shay Victoria, Alvarado Chance, Dimas V Vivian, Kamp Anna N
Аннотация
BACKGROUND: Two self-expanding transcatheter pulmonary valves (SETPVs), Harmony TPV (Medtronic) and Alterra Adaptive Prestent System with the Sapien 3 Valve (Edwards Lifesciences), treat pulmonary regurgitation in patients with a native or surgically repaired right ventricular outflow tract. Ventricular arrhythmias (VAs) are common after implantation.
OBJECTIVES: The purpose of this study was to identify the incidence of and risk factors for VA in the first 6 months after SETPV implantation.
METHODS: The multicenter SERVE registry included SETPV implantations at 25 U.S.
CENTERS: VA was defined as nonsustained ventricular tachycardia (VT), sustained monomorphic VT, polymorphic VT, or >1% ventricular ectopy on Holter monitoring.
RESULTS: A total of 513 SETPV implants (359 Harmony, 154 Alterra) were collected, with a median age of 28 years (Q1-Q3: 17-44 years) and no difference in baseline VA by valve type. Alterra patients were more likely (37%) than Harmony patients (26%; P = 0.014) to have VA during the procedural admission. At 6 months, predicted probability of VA burden decreased below baseline for Harmony patients (-6%; 95% CI: -10% to -2%; P < 0.001) and to baseline for Alterra (P = 0.53).
CONCLUSIONS: This large multicenter registry study of the natural history of VA after SETPV implantation showed VA to be frequent during the procedural admission, with Alterra patients having more VA than Harmony patients. VA burden decreased to lower than baseline at 6 months in Harmony patients and to baseline in Alterra patients.
OBJECTIVES: The purpose of this study was to identify the incidence of and risk factors for VA in the first 6 months after SETPV implantation.
METHODS: The multicenter SERVE registry included SETPV implantations at 25 U.S.
CENTERS: VA was defined as nonsustained ventricular tachycardia (VT), sustained monomorphic VT, polymorphic VT, or >1% ventricular ectopy on Holter monitoring.
RESULTS: A total of 513 SETPV implants (359 Harmony, 154 Alterra) were collected, with a median age of 28 years (Q1-Q3: 17-44 years) and no difference in baseline VA by valve type. Alterra patients were more likely (37%) than Harmony patients (26%; P = 0.014) to have VA during the procedural admission. At 6 months, predicted probability of VA burden decreased below baseline for Harmony patients (-6%; 95% CI: -10% to -2%; P < 0.001) and to baseline for Alterra (P = 0.53).
CONCLUSIONS: This large multicenter registry study of the natural history of VA after SETPV implantation showed VA to be frequent during the procedural admission, with Alterra patients having more VA than Harmony patients. VA burden decreased to lower than baseline at 6 months in Harmony patients and to baseline in Alterra patients.